Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

Summary

A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).

Timeline

Start

2023-05-12

Primary completion

2024-05-01

Completion

2024-05-01

Drugs

Indications